Lorlatinib (PF-06463922) is a potent, brain-penetrant oral ATP-competitive ALK/ROS1 inhibitor (sub-nanomolar Ki) that overcomes resistance mutants to disrupt oncogenic signaling and suppress tumor growth in ALK/ROS1-driven cancers.
Usually ships within 24 hours.